Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477123 | 0.85 | GRM5 (0.48) | GRM5VNN1 | |
| SCHEMBL1477071 | 0.84 | GRM5 (0.44) | GRM5VNN1CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL283358 | 0.84 | GRM5 (0.46) | GRM5VNN1CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL30200709 | 0.84 | GRM5 (0.46) | GRM5VNN1CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL1477817 | 0.83 | GRM5 (0.43) | GRM5VNN1CYP11B1CYP11B2 | |
| SCHEMBL1479159 | 0.82 | MTOR (0.44) | GRM5VNN1CYP11B1CYP11B2 | |
| SCHEMBL1477635 | 0.81 | KDR (0.42) | GRM5MAP2K1XDH | |
| SCHEMBL15190392 | 0.80 | GRM5 (0.44) | GRM5VNN1CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL1476830 | 0.79 | CYP11B2 (0.41) | GRM5CYP11B1CYP11B2 | |
| SCHEMBL1479219 | 0.78 | PIK3CG (0.42) | GRM5CYP11B1CYP11B2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | GRM5 48/4885VNN1 2112/4885PTPN11 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.